Beranda › Depresi › Connecticut
Uji klinis Depresi di Connecticut
15 studi untuk Depresi mencari peserta di lokasi di Connecticut.
Kota di Connecticut
Teks studi resmi (Bahasa Inggris)
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
- Yale University, New Haven
Menerima pesertaFase 2
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07610369A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07076407PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Mood Institute, Milford
- Yale School of Medicine, New Haven
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06713616A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07412756E-Mindfulness Approaches for Living After Breast Cancer
- Stamford Hospital/Bennett Cancer Center, Stamford
Menerima pesertaFase 3
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06748222A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06775379Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT06966401Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 21 hingga 65 · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT06671977Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life
- Yale University, New Haven
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05810259The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
Menerima pesertaFase 2
Usia 21 hingga 65 · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT05786066Stress and Pain in People Living With HIV
- The Yale Stress Center, New Haven
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 68 · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT06784908External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
- https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceL, Darien
Menerima pesertaStudi observasional
Usia 18 hingga 44 · Wanita · Diperbarui 15 Apr 2026 · NCT06788977Open-Label Psilocybin Study in Transdiagnostic Population
- Connecticut Mental Health Center - Yale School of Medicine, New Haven
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mar 2026 · NCT06442423Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.